FDA Warnings on Viekira Pak are Credit-Negative for AbbVie (ABBV) - Moody's
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
Moody's Investors Service commented that new warnings by the US Food and Drug Administration (FDA) on AbbVie's (NYSE: ABBV) hepatitis C drug Viekira Pak are credit negative because of lower sales potential. There is no impact on AbbVie's Baa1 ratings at this time, and the rating outlook remains negative.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbvie (ABBV) PT Raised to $195 at Barclays
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- HSBC Upgrades Xinte Energy Co Ltd (1799:HK) to Hold, 'cost cutting efforts likely to keep away from loss making'
Create E-mail Alert Related Categories
Credit RatingsRelated Entities
Moody's Investors ServiceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!